Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The material of the body and the cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer that covers the hard-shell capsule in the pre-locked state. The coating layer contains one or more (meth)acrylate copolymers, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The material of the body and the cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer that covers the hard-shell capsule in the pre-locked state. The coating layer contains one or more (meth)acrylate copolymers, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body in a pre-locked state or a final-locked state. The material of the body and cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer, containing one or more anionic cellulose(s), ethyl cellulose, and/or one or more starches comprising at least 35% by weight of amylose, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: A process can be used for preparing a polymer coated hard-shell capsule, filled with a fill containing a biologically active ingredient. The hard-shell capsule contains a body and a cap, and in a closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The material of the body and the cap contains an ethyl-, methyl-, or propyl-ether of cellulose, starch, or pullulan. The hard-shell capsule is coated with a coating layer that covers the hard-shell capsule in the pre-locked state. The coating layer contains one or more (meth)acrylate copolymers, where the coating layer is present in an amount of about 1 to 5.8 mg/cm2. The process involves providing the polymer-coated hard-shell capsule in the pre-locked state to a capsule-filling machine, separating the body and the cap, filling the body with the fill, and rejoining the body and the cap in the final-locked state.

Abstract: A process prepares a polymer-coated hard shell capsule, suitable as container for pharmaceutical or nutraceutical biologically active ingredients. The hard shell capsule can include a body and a cap. In the closed state, the cap overlaps the body either in a pre-locked state or in a final-locked state. The hard shell capsule can be provided in the pre-locked state and spray-coated with a coating solution, suspension, or dispersion that includes a polymer or a mixture of polymers to create a coating layer which covers the outer surface of the hard shell capsule in the pre-locked state.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention refers to process for preparing a bio-resorbable polyester in particulate form, comprising the steps: a) providing a bio-resorbable polyester with in the form of a dry polymer mass or in the form of a wet polymer mass; b) feeding the polymer mass from step a) into an extruder extruder with at least one degassing zone where the polymer mass is molten, extruded and degassed; c) discharging the degassed polymer mass out of the extruder; d) comminuting the discharged polymer mass to particles with —a bulk density of 0.3 g/ml or more, —a tapped density of 0.4 g/ml or more and —a specific surface area of 2.0 m2/g or less.

Abstract: The invention refers to process for preparing a bio-resorbable polyester in particulate form, comprising the steps: a) providing a bio-resorbable polyester with in the form of a dry polymer mass or in the form of a wet polymer mass; b) feeding the polymer mass from step a) into an extruder extruder with at least one degassing zone where the polymer mass is molten, extruded and degassed; c) discharging the degassed polymer mass out of the extruder; d) comminuting the discharged polymer mass to particles with —a bulk density of 0.3 g/ml or more, —a tapped density of 0.4 g/ml or more and —a specific surface area of 2.0 m2/g or less.

Abstract: The invention refers to a Process for preparing a bio-resorbable polyester the form of a powder with a bulk density of 0.3 g/ml or more, a tapped density of 0.4 g/ml or more and a specific surface area of 2.0 m2/g or less comprising the steps a. dissolving a bio-resorbable polyester in a first solvent to form a polymer solution, b. contacting the polymer solution with a second solvent which is a non-solvent for the bioresorbable polyester and which is mainly water to result the precipitation of the bio-resorbable polyester in the form of a wet polymer mass, c. pre-drying the wet polymer mass at a temperature below the TgO of the bio-resorbable polyester, d. comminuting the pre-dried polymer mass to polymer particles with a size below 10 mm, e. drying the comminuted polymer particles below the TgO of the bio-resorbable polyester to a residual water content of 1% or less by weight/weight, f.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of a neutral cellulosic compound and 1 to 25% by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.

Abstract: The invention refers to a Process for preparing a bio-resorbable polyester the form of a powder with a bulk density of 0.3 g/ml or more, a tapped density of 0.4 g/ml or more and a specific surface area of 2.0 m2/g or less comprising the steps a. dissolving a bio-resorbable polyester in a first solvent to form a polymer solution, b. contacting the polymer solution with a second solvent which is a non-solvent for the bioresorbable polyester and which is mainly water to result the precipitation of the bio-resorbable polyester in the form of a wet polymer mass, c. pre-drying the wet polymer mass at a temperature below the TgO of the bio-resorbable polyester, d. comminuting the pre-dried polymer mass to polymer particles with a size below 10 mm, e. drying the comminuted polymer particles below the TgO of the bio-resorbable polyester to a residual water content of 1% or less by weight/weight, f.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol, whereby the ethanol resistance conferring coating layer comprises at least 70% by weight of a mixture of a polymeric portion a) and an excipients portion b), with the polymeric portion a) is consisting of a water insoluble essentially neutral vinyl polymer or vinyl copolymer and the excipients portion b) is consisting of the excipients b1) 100 to 250% by weight of a non-porous inert lubricant, b2) 1 to 35% by weight of a cellulosic compound, b3) 0.1 to 25% by weight of an emulsifier and additionally or alternatively to b3), b4) 0.

Abstract: The invention relates to a controlled release pharmaceutical composition, comprising a core, comprising a pharmaceutical active ingredient, whereby the core is coated by an ethanol resistance conferring coating layer which has the effect of conferring the release profile of the pharmaceutical active ingredient to be resistant against the influence of ethanol. The coating layer comprises a polymeric portion consisting of a water-insoluble neutral vinyl polymer or vinyl copolymer and an amino methacrylate copolymer and an excipients portion consisting of a lubricant, an emulsifier, a plasticizer and optionally a cellulosic compound.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising at least one pharmaceutical active ingredient, with the exception of opioids, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer or copolymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of at least one neutral cellulosic compound and 1 to 25% by weight of at least one emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40 95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5 60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250 % by weight of a non-porous inert lubricant, 1 to 35 % by weight of a neutral cellulosic compound and 1 to 25 % by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: A process for measuring parameters of organs and tissues, especially blood flow through an organ, particularly the liver, is based on a medical technology apparatus that can be constructed in modular fashion. The preferred process uses the hydrogen clearance method to determine blood flow. The preferred apparatus includes at least one measuring instrument and at least one measuring or therapy sensor that is detachable from that instrument. Additional connecting elements make it possible to construct an individually adapted measurement array. For a monitoring and checking operation, both the sensors or therapy heads, and the various connecting elements are equipped with electronic code elements which can be systematically read and evaluated by at least one of the measuring instruments used.

Abstract: For the temporary fixation of teeth, teeth rows or jaw parts, the device has a wire (9), on which annular composite carriers (7) are movably arranged. The composite carriers (7) can, for example, be flexible synthetic material rings of cross-section in the form of a truncated cone, through which the wire (9) is guided by means of two holes (8) arranged in the walls, which lie opposite one another, of the composite carriers (7).The new splint makes possible the exact positioning of the composite carriers (7) which are arranged movably on the wire (9) and can be deformed at will by hand.

Abstract: Thread clamp for a warp end tying-in machine. In such a clamp, cam control means mechanically related to the remainder of the machine are provided for positively opening the clamps in order that the thread may be inserted therein without hindrance. The clamp is thereupon permitted to close and the mechanical means retracted therefrom in order that the clamp may be held in closed condition solely by the tension of adjustable resilient means applied thereto. With the mechanical means remaining inoperative with respect to the clamp, same is moved through a conventional operating cycle and back to its point of beginning. Mechanical means are thereupon again activated to open the clamp against the urging of said spring whereby the thread may be removed without restriction therefrom.